Symbols

GENB

Generate Biomedicines·NASDAQ

--(--)

Key Stats

0.0000DAY`S RANGE0.0000

0.000052 WK RANGE0.0000

Open

0.0000

Prev.Close

0.0000

%Range

Turnover

Avg Vol(4W)

Market Cap

Div.Yield

P/E(TTM)

EPS(TTM)

Beta

Free Float

Shares Outstanding

%Turnover

P/E(DYN)

P/B

BVPS

High

0.0000

Low

0.0000

52 Week High

0.0000

52 Week Low

0.0000

About GENB

Generate Biomedicines, Inc.

A clinical stage generative biology company

Industry

Biological Technology

Established Date

Listing Date

02/27/2026

Exchange

NASDAQ Stock Exchange

Full-time Employees

312

Fiscal Year Ends

12-31

Website

www.generatebiomedicines.com

Security Type

Common stock

Office address

101 South Street Suite 900 Somerville MA 02143

Business

Introduction

Generate Biomedicines, Inc., was incorporated under the laws of the State of Delaware in August 2018. As a clinical stage generative biology company, the company pioneered an artificial intelligence-driven biotechnology platform called Generate Platform, which combines computational models with scalable biological hardware to design and develop novel therapeutic proteins. Its most advanced drug candidate, GB-0895, is a computationally engineered anti-TSLP monoclonal antibody that is currently in a pivotal Phase 3 trial for severe asthma. The platform's capabilities have been further demonstrated by advancing two additional oncology drug candidates to Phase 1 trials in 2026.